Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Importance of FDG-PET (Fluorodeoxyglucose Positron Emission Tomography) in Staging and Response Assessment of Hairy Cell Leukemia (HCL)

Alessandro Mancini, Luca De Carolis, Monia Capponi, Flavio Falcinelli, Edoardo Simonetti, Andrea Lupi, Jacopo Olivieri, Francesco Zaja, Matteo Porcari, Nicodemo Baffa, Brunangelo Falini, Enrico Tiacci

Blood (2023) 142 (Supplement 1): 3044.

https://doi.org/10.1182/blood-2023-177603

Published: 2023

Journal Articles

Real-Life Efficacy and Safety of Vemurafenib Plus Rituximab (V+R) in Relapsed or Refractory Hairy Cell Leukemia: A Multi-Center Retrospective Study (HCL-PG03R)

Blood (2023) 142 (Supplement 1): 3027.

https://doi.org/10.1182/blood-2023-178648

Published: 2023

Journal Articles

Efficacy and Safety of Obinutuzumab in Relapsed or Refractory Hairy Cell Leukemia (R/R HCL): An Italian Multicenter Phase-2 Academic Trial (HCL-PG04)

Enrico Tiacci, Luca De Carolis, Monia Capponi, Flavio Falcinelli, Francesco Zaja, Alessandro Pulsoni, Edoardo Simonetti, Elisa Montechiarello, Alessandra Romano, Jacopo Olivieri, Alessandro Mancini, Gianna Maria D'Elia, Robin Foa, Maurizio Frezzato, Brunangelo Falini

Blood (2023) 142 (Supplement 1): 4398.

https://doi.org/10.1182/blood-2023-180035

Published: 2023

Journal Articles

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Blood (2023) 141 (15): 1846–1857.

https://doi.org/10.1182/blood.2022018108

Published: 2023

Includes: Supplemental data

Journal Articles

How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors

Brunangelo Falini, Luca De Carolis, Enrico Tiacci

Blood (2022) 139 (15): 2294–2305.

https://doi.org/10.1182/blood.2021013502

Published: 2022

Journal Articles

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML

Blood (2021) 138 (25): 2696–2701.

https://doi.org/10.1182/blood.2021012732

Published: 2021

Includes: Supplemental data

Journal Articles

Long-Term Treatment of Hairy Cell Leukemia Patients with Interferon: Clinical and Molecular Aspects

Giovanni Manfredi Assanto, MD, Costantino Riemma, MD, Francesco Malaspina, MD, Salvatore Perrone, MD, Maria Lucia De Luca, MD, Giorgia Annechini, MD, Gianna Maria D'elia, Maurizio Martelli, MD, Robin Foà, MD, Enrico Tiacci, Alessandro Pulsoni, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-136660

Published: 2020

Journal Articles

Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136633

Published: 2020

Journal Articles

Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma

Blood (2018) 131 (22): 2454–2465.

https://doi.org/10.1182/blood-2017-11-814913

Published: 2018

Includes: Supplemental data

Journal Articles

The Chemotherapy-Free Combination of Vemurafenib and Rituximab Produces Deep and Durable Responses in Relapsed or Refractory Hairy Cell Leukemia (HCL) Patients

Enrico Tiacci, Luca De Carolis, Francesco Zaja, MD, Monia Capponi, Achille Ambrosetti, Eugenio Lucia, Agostino Antolino, Alessandro Pulsoni, MD, Samantha Ferrari, MD, Pier Luigi Zinzani, MD, Luigi Rigacci, Gianluca Gaidano, MD PhD, Roberta Della Seta, Natalia Frattarelli, Paolo Falcucci, Giuseppe Visani, Robin Foà, MD, Brunangelo Falini, MD

Blood (2017) 130 (Supplement 1): 409.

https://doi.org/10.1182/blood.V130.Suppl_1.409.409

Published: 2017

Journal Articles

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Blood (2017) 129 (5): 553–560.

https://doi.org/10.1182/blood-2016-01-689422

Published: 2017

Journal Articles

Identification and Characterization of Novel Rare Nucleophosmin ( NPM1 ) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses

Maria Paola Martelli, MD PhD, Roberta Rossi, PhD, Emanuela Varasano, PhD, Giorgina Specchia, MD, Francesco Di Raimondo, MD, Giuseppe Avvisati, MD, Enrico Tiacci, MD PhD, Franca Falzetti, MD, Paolo Sportoletti, MD PhD, Brunangelo Falini, MD

Blood (2016) 128 (22): 1717.

https://doi.org/10.1182/blood.V128.22.1717.1717

Published: 2016

Journal Articles

New Recurrently Mutated Genes in Classical Hodgkin Lymphoma Revealed By Whole-Exome Sequencing of Microdissected Tumor Cells

Enrico Tiacci#, Alexander Penson#, Gianluca Schiavoni#, Erik Ladewig#, Elisabetta Fortini#, Yuchun Wang, Ariele Spanhol-Rosseto, Alessandra Venanzi, Alessandro M. Gianni, Simonetta Viviani, MD, Antonello Cabras, Barbara Crescenzi, Cristina Mecucci, MD PhD, Laura Pasqualucci°, Raul Rabadan°, Brunangelo Falini°

Blood (2016) 128 (22): 1088.

https://doi.org/10.1182/blood.V128.22.1088.1088

Published: 2016

Journal Articles

Vemurafenib Plus Rituximab in Hairy Cell Leukemia: A Promising Chemotherapy-Free Regimen for Relapsed or Refractory Patients

Enrico Tiacci, Luca De Carolis, Francesco Zaja, Achille Ambrosetti, MD, Eugenio Lucia, Agostino Antolino, Alessandro Pulsoni, MD, Samantha Ferrari, MD, Pier Luigi Zinzani, Gianluca Gaidano, MD PhD, Robin Foà, Brunangelo Falini

Blood (2016) 128 (22): 1214.

https://doi.org/10.1182/blood.V128.22.1214.1214

Published: 2016

Journal Articles

A Distributed International Patient Data Registry for Hairy Cell Leukemia

Leslie A. Andritsos, MD, Michael R. Grever, MD, Mirela Anghelina, MD, Claire E Dearden, MD FRCP, FRCPath, Monica Else, MA, MSc, James S. Blachly, MD, Omkar Lele, MS, MBA, Farhad Ravandi, MD, Clive S Zent, MD, James B. Johnston, MD FRCP, Versha Banerji, MD FRCP, Francesco Forconi, MD DM, PhD FRCPath, Anthony D. Ho, MD, Thorsten Zenz, Sascha Dietrich, Judit Demeter, MD PhD, Jacqueline C. Barrientos, MD, Jan A. Burger, MD PhD, Timothy G. Call, MD, Nicholas Chiorazzi, MD, Daniel J. DeAngelo, MD PhD, Julio Delgado, MD, Andrei Fagarasanu, MD PhD, Brunangelo Falini, Alessandro Gozzetti, MD, Jeffrey Jones, MD MPH, Gunnar Juliusson, MD, Eric H. Kraut, MD, Robert J. Kreitman, MD, Loree Larratt, MD, Francesco Lauria, MD, Gerard Lozanski, MD, Emili Montserrat, MD, Sameer A. Parikh, MD, Jae H. Park, MD, Aaron Polliack, MD, Graeme R. Quest, MD MSc, Kanti R. Rai, MD, Tadeusz Robak, MD PhD, Alan Saven, MD, Tamar Tadmor, MD, Martin S. Tallman, MD, Constantine S. Tam, MBBS, Enrico Tiacci, MD, Xavier Troussard, MD PhD, Omar Abdel-Wahab, MD, Pier Luigi Zinzani, MD, PhD, Christopher Heckler, BS, MBA, Philip R.O. Payne, PhD

Blood (2016) 128 (22): 5986.

https://doi.org/10.1182/blood.V128.22.5986.5986

Published: 2016

Journal Articles

BRAF V600E mutation in hairy cell leukemia: from bench to bedside

Brunangelo Falini, Maria Paola Martelli, Enrico Tiacci

Blood (2016) 128 (15): 1918–1927.

https://doi.org/10.1182/blood-2016-07-418434

Published: 2016

Journal Articles

The genetics of nodal marginal zone lymphoma

Blood (2016) 128 (10): 1362–1373.

https://doi.org/10.1182/blood-2016-02-696757

Published: 2016

Includes: Supplemental data

Journal Articles

Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts

Blood (2016) 127 (2): 221–232.

https://doi.org/10.1182/blood-2014-12-614503

Published: 2016

Includes: Supplemental data

Journal Articles

Arsenic trioxide and all- trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1 -mutated AML cells

Maria Paola Martelli, Ilaria Gionfriddo, Federica Mezzasoma, Francesca Milano, Sara Pierangeli, Floriana Mulas, Roberta Pacini, Alessia Tabarrini, Valentina Pettirossi, Roberta Rossi, Calogero Vetro, Lorenzo Brunetti, Paolo Sportoletti, Enrico Tiacci, Francesco Di Raimondo, Brunangelo Falini

Blood (2015) 125 (22): 3455–3465.

https://doi.org/10.1182/blood-2014-11-611459

Published: 2015

Includes: Supplemental data

Journal Articles

BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity

Valentina Pettirossi, Alessia Santi, Elisa Imperi, Guido Russo, Alessandra Pucciarini, Barbara Bigerna, Gianluca Schiavoni, Elisabetta Fortini, Ariele Spanhol-Rosseto, Paolo Sportoletti, Roberta Mannucci, Maria Paola Martelli, Ludger Klein-Hitpass, Brunangelo Falini, Enrico Tiacci

Blood (2015) 125 (8): 1207–1216.

https://doi.org/10.1182/blood-2014-10-603100

Published: 2015

Includes: Supplemental data

NARROW

Importance of FDG-PET (Fluorodeoxyglucose Positron Emission Tomography) in Staging and Response Assessment of Hairy Cell Leukemia (HCL)

Real-Life Efficacy and Safety of Vemurafenib Plus Rituximab (V+R) in Relapsed or Refractory Hairy Cell Leukemia: A Multi-Center Retrospective Study (HCL-PG03R)

Efficacy and Safety of Obinutuzumab in Relapsed or Refractory Hairy Cell Leukemia (R/R HCL): An Italian Multicenter Phase-2 Academic Trial (HCL-PG04)

Overlapping features of therapy-related and de novo NPM1 -mutated AML

How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML

Long-Term Treatment of Hairy Cell Leukemia Patients with Interferon: Clinical and Molecular Aspects

Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience

Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma

The Chemotherapy-Free Combination of Vemurafenib and Rituximab Produces Deep and Durable Responses in Relapsed or Refractory Hairy Cell Leukemia (HCL) Patients

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Identification and Characterization of Novel Rare Nucleophosmin ( NPM1 ) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses

New Recurrently Mutated Genes in Classical Hodgkin Lymphoma Revealed By Whole-Exome Sequencing of Microdissected Tumor Cells

Vemurafenib Plus Rituximab in Hairy Cell Leukemia: A Promising Chemotherapy-Free Regimen for Relapsed or Refractory Patients

A Distributed International Patient Data Registry for Hairy Cell Leukemia

BRAF V600E mutation in hairy cell leukemia: from bench to bedside

The genetics of nodal marginal zone lymphoma

Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts

Arsenic trioxide and all- trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1 -mutated AML cells

BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only